<?xml version="1.0" encoding="utf-8"?> <rss version="2.0"> <channel xmlns:dc="http://dublincore.org/documents/dcmi-namespace/" xmlns:media="http://search.yahoo.com/mrss/"> <title>Aeolus Pharmaceuticals, Inc.</title> <link>https://www.globenewswire.com/rssfeed/organization/xqwgZzmy-R3FB-au9qDhiQ==</link> <description>Contains the last 20 releases</description> <copyright>Copyright 2017, Aeolus Pharmaceuticals, Inc.</copyright> <managingEditor>newsdesk@globenewswire.com (NewsDesk)</managingEditor> <lastBuildDate>Thu, 08 Jun 2017 14:35:00 GMT</lastBuildDate> <webMaster>webmaster@globenewswire.com (Webmaster)</webMaster> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2017/06/08/1306799/0/en/Aeolus-Announces-FDA-Fast-Track-Designation-Granted-to-AEOL-10150-for-Treatment-of-Patients-With-Lung-Acute-Radiation-Syndrome-Following-a-Radiologial-or-Nuclear-Event.html</guid> <link>https://www.globenewswire.com/news-release/2017/06/08/1306799/0/en/Aeolus-Announces-FDA-Fast-Track-Designation-Granted-to-AEOL-10150-for-Treatment-of-Patients-With-Lung-Acute-Radiation-Syndrome-Following-a-Radiologial-or-Nuclear-Event.html</link> <title>Aeolus Announces FDA Fast Track Designation Granted to AEOL 10150 for Treatment of Patients With Lung Acute Radiation Syndrome Following a Radiologial or Nuclear Event</title> <description><![CDATA[<p align="center"> </p>]]></description> <pubDate>Thu, 08 Jun 2017 14:35 GMT</pubDate> <dc:identifier>1306799</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Aeolus Pharmaceuticals</dc:contributor> <dc:modified>Wed, 14 Feb 2018 05:50 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2017/05/15/1306797/0/en/Aeolus-Announces-Second-Quarter-Financial-Results-for-Fiscal-Year-2017.html</guid> <link>https://www.globenewswire.com/news-release/2017/05/15/1306797/0/en/Aeolus-Announces-Second-Quarter-Financial-Results-for-Fiscal-Year-2017.html</link> <title>Aeolus Announces Second Quarter Financial Results for Fiscal Year 2017</title> <description><![CDATA[<p><span class="mw_region">MISSION VIEJO, CA</span><span>--(Marketwired - May 15, 2017) - </span><a href="http://www.aeoluspharma.com/" rel="nofollow" title="Aeolus Pharmaceuticals, Inc.">Aeolus Pharmaceuticals, Inc.</a> (<exchange name="OTCQB">OTCQB</exchange>: <ticker name="AOLS">AOLS</ticker>), a biotechnology company developing compounds to protect against fibrosis, inflammation, nerve damage and infection announced today financial results for the three months ended March 31, 2017. </p>]]></description> <pubDate>Mon, 15 May 2017 21:00 GMT</pubDate> <dc:identifier>1306797</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Aeolus Pharmaceuticals</dc:contributor> <dc:modified>Wed, 14 Feb 2018 05:50 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2017/03/15/1306795/0/en/AEOL-20415-Protects-Lungs-Against-Infection-in-Animal-Model-of-Cystic-Fibrosis.html</guid> <link>https://www.globenewswire.com/news-release/2017/03/15/1306795/0/en/AEOL-20415-Protects-Lungs-Against-Infection-in-Animal-Model-of-Cystic-Fibrosis.html</link> <title>AEOL 20415 Protects Lungs Against Infection in Animal Model of Cystic Fibrosis</title> <description><![CDATA[<p><span class="mw_region">MISSION VIEJO, CA</span><span>--(Marketwired - March 15, 2017) - </span></p>]]></description> <pubDate>Wed, 15 Mar 2017 13:00 GMT</pubDate> <dc:identifier>1306795</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Aeolus Pharmaceuticals</dc:contributor> <dc:modified>Wed, 14 Feb 2018 05:50 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2017/02/22/1306793/0/en/Aeolus-Initiates-Phase-1-Study-of-AEOL-10150-in-Healthy-Normal-Volunteers.html</guid> <link>https://www.globenewswire.com/news-release/2017/02/22/1306793/0/en/Aeolus-Initiates-Phase-1-Study-of-AEOL-10150-in-Healthy-Normal-Volunteers.html</link> <title>Aeolus Initiates Phase 1 Study of AEOL 10150 in Healthy Normal Volunteers</title> <description><![CDATA[<p><span class="mw_region">MISSION VIEJO, CA</span><span>--(Marketwired - February 22, 2017) - </span><a href="http://www.aeoluspharma.com/" rel="nofollow" title="Aeolus Pharmaceuticals, Inc.">Aeolus Pharmaceuticals, Inc.</a> (<exchange name="OTCQB">OTCQB</exchange>: <ticker name="AOLS">AOLS</ticker>), a biotechnology company developing compounds to protect against fibrosis, inflammation, nerve damage and infection, announced today the initiation of a phase 1 study with its lead compound AEOL 10150. The phase 1 study is an open-label, single center, dose-escalation study to evaluate the safety, tolerability, and pharmacokinetics of an escalating single dose of AEOL 10150 administered by subcutaneous injection in healthy subjects. </p>]]></description> <pubDate>Wed, 22 Feb 2017 20:13 GMT</pubDate> <dc:identifier>1306793</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Aeolus Pharmaceuticals</dc:contributor> <dc:modified>Wed, 14 Feb 2018 05:50 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2016/12/21/1306791/0/en/Aeolus-Announces-Fiscal-Year-2016-Financial-Results.html</guid> <link>https://www.globenewswire.com/news-release/2016/12/21/1306791/0/en/Aeolus-Announces-Fiscal-Year-2016-Financial-Results.html</link> <title>Aeolus Announces Fiscal Year 2016 Financial Results</title> <description><![CDATA[<p><span class="mw_region">MISSION VIEJO, CA</span><span>--(Marketwired - December 21, 2016) - </span> <a href="http://www.aeoluspharma.com/" rel="nofollow" title="Aeolus Pharmaceuticals, Inc.">Aeolus Pharmaceuticals, Inc.</a> (<exchange name="OTCQB">OTCQB</exchange>: <ticker name="AOLS">AOLS</ticker>), a biotechnology company developing compounds to protect against fibrosis, inflammation, nerve damage and infection announced today financial results for the three months and twelve months ended September 30, 2016.</p>]]></description> <pubDate>Wed, 21 Dec 2016 13:00 GMT</pubDate> <dc:identifier>1306791</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Aeolus Pharmaceuticals</dc:contributor> <dc:modified>Wed, 14 Feb 2018 05:50 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2016/09/19/1306789/0/en/Aeolus-Announces-Publication-of-Additional-Data-Demonstrating-Efficacy-of-AEOL-10150-in-Sulfur-Mustard-Exposure-in-Journal-Toxicological-Sciences.html</guid> <link>https://www.globenewswire.com/news-release/2016/09/19/1306789/0/en/Aeolus-Announces-Publication-of-Additional-Data-Demonstrating-Efficacy-of-AEOL-10150-in-Sulfur-Mustard-Exposure-in-Journal-Toxicological-Sciences.html</link> <title>Aeolus Announces Publication of Additional Data Demonstrating Efficacy of AEOL 10150 in Sulfur Mustard Exposure in Journal "Toxicological Sciences"</title> <description><![CDATA[<p><span class="mw_region">MISSION VIEJO, CA</span><span>--(Marketwired - September 19, 2016) - </span></p>]]></description> <pubDate>Mon, 19 Sep 2016 13:19 GMT</pubDate> <dc:identifier>1306789</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Aeolus Pharmaceuticals</dc:contributor> <dc:modified>Wed, 14 Feb 2018 05:50 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2016/09/06/1306787/0/en/Aeolus-Announces-Positive-Data-Confirming-Efficacy-of-AEOL-10150-as-a-Medical-Countermeasure-Against-Sulfur-Mustard-Gas.html</guid> <link>https://www.globenewswire.com/news-release/2016/09/06/1306787/0/en/Aeolus-Announces-Positive-Data-Confirming-Efficacy-of-AEOL-10150-as-a-Medical-Countermeasure-Against-Sulfur-Mustard-Gas.html</link> <title>Aeolus Announces Positive Data Confirming Efficacy of AEOL 10150 as a Medical Countermeasure Against Sulfur Mustard Gas</title> <description><![CDATA[<p><span class="mw_region">MISSION VIEJO, CA</span><span>--(Marketwired - September 06, 2016) - </span></p>]]></description> <pubDate>Tue, 06 Sep 2016 12:30 GMT</pubDate> <dc:identifier>1306787</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Aeolus Pharmaceuticals</dc:contributor> <dc:modified>Wed, 14 Feb 2018 05:50 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2016/08/31/1306785/0/en/Aeolus-Pharmaceuticals-to-Present-at-Aegis-Growth-Conference-on-September-22-2016.html</guid> <link>https://www.globenewswire.com/news-release/2016/08/31/1306785/0/en/Aeolus-Pharmaceuticals-to-Present-at-Aegis-Growth-Conference-on-September-22-2016.html</link> <title>Aeolus Pharmaceuticals to Present at Aegis Growth Conference on September 22, 2016</title> <description><![CDATA[<p><span class="mw_region">MISSION VIEJO, CA</span><span>--(Marketwired - August 31, 2016) - </span> <a href="http://www.aeoluspharma.com/" rel="nofollow" title="Aeolus Pharmaceuticals, Inc.">Aeolus Pharmaceuticals, Inc.</a> (<exchange name="OTCQB">OTCQB</exchange>: <ticker name="AOLS">AOLS</ticker>), a biotechnology company developing compounds to protect against fibrosis, inflammation, nerve damage and infection, announced today that it will be presenting at the 2016 Aegis Growth Conference on Thursday, September 22nd at 9:00AM PDT / 12 Noon EDT at the Encore at Wynn in Las Vegas. David C. Cavalier, Chairman and Chief Financial Officer will be giving the presentation and meeting with investors. </p>]]></description> <pubDate>Wed, 31 Aug 2016 13:09 GMT</pubDate> <dc:identifier>1306785</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Aeolus Pharmaceuticals</dc:contributor> <dc:modified>Wed, 14 Feb 2018 05:50 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2016/08/15/1306783/0/en/Aeolus-Announces-Third-Quarter-Fiscal-Year-2016-Financial-Results.html</guid> <link>https://www.globenewswire.com/news-release/2016/08/15/1306783/0/en/Aeolus-Announces-Third-Quarter-Fiscal-Year-2016-Financial-Results.html</link> <title>Aeolus Announces Third Quarter Fiscal Year 2016 Financial Results</title> <description><![CDATA[<p><span class="mw_region">MISSION VIEJO, CA</span><span>--(Marketwired - August 15, 2016) - </span> <a href="http://www.aeoluspharma.com/" rel="nofollow" title="Aeolus Pharmaceuticals, Inc.">Aeolus Pharmaceuticals, Inc.</a> (<exchange name="OTCQB">OTCQB</exchange>: <ticker name="AOLS">AOLS</ticker>), a biotechnology company developing compounds to protect against fibrosis, inflammation, nerve damage and infection, announced today financial results for the nine months ended June 30, 2016. </p>]]></description> <pubDate>Mon, 15 Aug 2016 20:29 GMT</pubDate> <dc:identifier>1306783</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Aeolus Pharmaceuticals</dc:contributor> <dc:modified>Wed, 14 Feb 2018 05:50 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2016/05/23/1306781/0/en/Aeolus-Pharmaceuticals-to-Present-at-LD-Micro-Invitational-Conference.html</guid> <link>https://www.globenewswire.com/news-release/2016/05/23/1306781/0/en/Aeolus-Pharmaceuticals-to-Present-at-LD-Micro-Invitational-Conference.html</link> <title>Aeolus Pharmaceuticals to Present at LD Micro Invitational Conference</title> <description><![CDATA[<p> <span class="mw_region">MISSION VIEJO, CA</span><span>--(Marketwired - May 23, 2016) - </span> <a href="http://www.aeoluspharma.com/" rel="nofollow" title="Aeolus Pharmaceuticals, Inc.">Aeolus Pharmaceuticals, Inc.</a> (<exchange name="OTCQB">OTCQB</exchange>: <ticker name="AOLS">AOLS</ticker>), a biotechnology company developing compounds to protect against fibrosis, inflammation, nerve damage and infection announced today that it will be presenting at the 6<sup>th</sup> annual LD Micro Invitational on Tuesday, June 7th at 9:00AM PDT / 12 Noon EDT at the Luxe Sunset Boulevard Hotel in Los Angeles. David C. Cavalier, Chairman and Chief Financial Officer will be giving the presentation and meeting with investors. </p>]]></description> <pubDate>Mon, 23 May 2016 12:00 GMT</pubDate> <dc:identifier>1306781</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Aeolus Pharmaceuticals</dc:contributor> <dc:modified>Wed, 14 Feb 2018 05:50 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2016/05/16/1306779/0/en/Aeolus-Announces-Second-Quarter-Fiscal-Year-2016-Financial-Results-and-Investor-Update-Call.html</guid> <link>https://www.globenewswire.com/news-release/2016/05/16/1306779/0/en/Aeolus-Announces-Second-Quarter-Fiscal-Year-2016-Financial-Results-and-Investor-Update-Call.html</link> <title>Aeolus Announces Second Quarter Fiscal Year 2016 Financial Results and Investor Update Call</title> <description><![CDATA[<p> <span class="mw_region">MISSION VIEJO, CA</span><span>--(Marketwired - May 16, 2016) - </span> <a href="http://www.aeoluspharma.com/" rel="nofollow" title="Aeolus Pharmaceuticals, Inc.">Aeolus Pharmaceuticals, Inc.</a> (<exchange name="OTCQB">OTCQB</exchange>: <ticker name="AOLS">AOLS</ticker>), a biotechnology company developing compounds to protect against fibrosis, inflammation, nerve damage and infection announced today financial results for the three months ended March 31, 2016. The Company also announced a conference call to update investors on its development programs, including its partnership with the Biomedical Advanced Research and Development Authority ("BARDA") for the development of AEOL-10150 ("10150") as treatment for the pulmonary and delayed effects of acute radiation exposure ("Lung-ARS"). </p>]]></description> <pubDate>Mon, 16 May 2016 12:00 GMT</pubDate> <dc:identifier>1306779</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Aeolus Pharmaceuticals</dc:contributor> <dc:modified>Wed, 14 Feb 2018 05:50 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2016/04/18/1306777/0/en/European-Patent-Issued-and-Patent-Allowed-in-Japan-for-Aeolus-Parkinson-s-Disease-Compound-AEOL-11114.html</guid> <link>https://www.globenewswire.com/news-release/2016/04/18/1306777/0/en/European-Patent-Issued-and-Patent-Allowed-in-Japan-for-Aeolus-Parkinson-s-Disease-Compound-AEOL-11114.html</link> <title>European Patent Issued and Patent Allowed in Japan for Aeolus' Parkinson's Disease Compound AEOL 11114</title> <description><![CDATA[<p> <span class="mw_region">MISSION VIEJO, CA </span><span>--(Marketwired - April 18, 2016) - </span>Aeolus Pharmaceuticals (<exchange name="OTCQB">OTCQB</exchange>: <ticker name="AOLS">AOLS</ticker>)</p>]]></description> <pubDate>Mon, 18 Apr 2016 12:00 GMT</pubDate> <dc:identifier>1306777</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Aeolus Pharmaceuticals</dc:contributor> <dc:modified>Wed, 14 Feb 2018 05:50 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2016/02/22/1306775/0/en/Aeolus-Announces-Removal-of-FDA-Clinical-Hold-on-AEOL-10150-Initiation-of-Phase-1-Study-in-Healthy-Volunteers-Planned-for-2nd-Quarter-2016.html</guid> <link>https://www.globenewswire.com/news-release/2016/02/22/1306775/0/en/Aeolus-Announces-Removal-of-FDA-Clinical-Hold-on-AEOL-10150-Initiation-of-Phase-1-Study-in-Healthy-Volunteers-Planned-for-2nd-Quarter-2016.html</link> <title>Aeolus Announces Removal of FDA Clinical Hold on AEOL 10150; Initiation of Phase 1 Study in Healthy Volunteers Planned for 2nd Quarter 2016</title> <description><![CDATA[<p> <span class="mw_region">MISSION VIEJO, CA</span><span>--(Marketwired - February 22, 2016) - </span> <a href="http://www.aeoluspharma.com/" rel="nofollow" title="Aeolus Pharmaceuticals, Inc.">Aeolus Pharmaceuticals, Inc.</a>(<exchange name="OTCQB">OTCQB</exchange>: <ticker name="AOLS">AOLS</ticker>), a biotechnology company developing compounds to protect against fibrosis, inflammation, nerve damage and infection announced today that it has received notice that the U.S. Food & Drug Administration ("FDA") has removed the clinical hold on the Company's Investigational New Drug application for AEOL 10150 ("10150") as a treatment for the lung and delayed effects of acute radiation exposure ("Lung-ARS"). The lifting of the clinical hold allows the Company to initiate its planned human safety study in healthy normal volunteers.</p>]]></description> <pubDate>Mon, 22 Feb 2016 13:00 GMT</pubDate> <dc:identifier>1306775</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Aeolus Pharmaceuticals</dc:contributor> <dc:modified>Wed, 14 Feb 2018 05:50 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2016/02/16/1306773/0/en/Aeolus-Announces-First-Quarter-Fiscal-Year-2016-Financial-Results.html</guid> <link>https://www.globenewswire.com/news-release/2016/02/16/1306773/0/en/Aeolus-Announces-First-Quarter-Fiscal-Year-2016-Financial-Results.html</link> <title>Aeolus Announces First Quarter Fiscal Year 2016 Financial Results</title> <description><![CDATA[<p> <span class="mw_region">MISSION VIEJO, CA</span><span>--(Marketwired - February 16, 2016) - </span> <a href="http://www.aeoluspharma.com/" rel="nofollow" title="Aeolus Pharmaceuticals, Inc.">Aeolus Pharmaceuticals, Inc.</a> (<exchange name="OTCQB">OTCQB</exchange>: <ticker name="AOLS">AOLS</ticker>), a biotechnology company developing compounds to protect against fibrosis, inflammation, nerve damage and infection announced today financial results for the three months ended December 31, 2015.</p>]]></description> <pubDate>Tue, 16 Feb 2016 22:08 GMT</pubDate> <dc:identifier>1306773</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Aeolus Pharmaceuticals</dc:contributor> <dc:modified>Wed, 14 Feb 2018 05:50 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2015/12/18/1306771/0/en/Aeolus-Announces-Fiscal-Year-2015-Financial-Results.html</guid> <link>https://www.globenewswire.com/news-release/2015/12/18/1306771/0/en/Aeolus-Announces-Fiscal-Year-2015-Financial-Results.html</link> <title>Aeolus Announces Fiscal Year 2015 Financial Results</title> <description><![CDATA[<p> <span class="mw_region">MISSION VIEJO, CA</span><span>--(Marketwired - December 18, 2015) - </span> <a href="http://www.aeoluspharma.com/" rel="nofollow" title="Aeolus Pharmaceuticals, Inc.">Aeolus Pharmaceuticals, Inc.</a> (<exchange name="OTCQB">OTCQB</exchange>: <ticker name="AOLS">AOLS</ticker>), a biotechnology company developing compounds to protect against radiological and chemical threats in partnership with the US Government, announced today financial results for the three months and twelve months ended September 30, 2015.</p>]]></description> <pubDate>Fri, 18 Dec 2015 22:09 GMT</pubDate> <dc:identifier>1306771</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Aeolus Pharmaceuticals</dc:contributor> <dc:modified>Wed, 14 Feb 2018 05:50 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2015/12/15/1306769/0/en/Aeolus-Announces-6-75-Million-Private-Placement-Financing.html</guid> <link>https://www.globenewswire.com/news-release/2015/12/15/1306769/0/en/Aeolus-Announces-6-75-Million-Private-Placement-Financing.html</link> <title>Aeolus Announces $6.75 Million Private Placement Financing</title> <description><![CDATA[<p> <span class="mw_region">MISSION VIEJO, CA</span><span>--(Marketwired - December 15, 2015) - </span> <a href="http://www.aeoluspharma.com/" rel="nofollow" title="Aeolus Pharmaceuticals, Inc.">Aeolus Pharmaceuticals, Inc.</a> (<exchange name="OTCQB">OTCQB</exchange>: <ticker name="AOLS">AOLS</ticker>), a biotechnology company developing compounds to protect against fibrosis, inflammation, nerve damage and infection announced today that it has entered into definitive agreements with certain institutional and other accredited investors to raise gross proceeds of $6.75 million in a private placement financing. The investors comprised both new and existing investors in the Company, including entities associated with BVF Partners L.P., a leading life sciences investment firm, which manages the Biotechnology Value Fund family of funds ("BVF"). </p>]]></description> <pubDate>Tue, 15 Dec 2015 20:22 GMT</pubDate> <dc:identifier>1306769</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Aeolus Pharmaceuticals</dc:contributor> <dc:modified>Wed, 14 Feb 2018 05:50 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2015/12/14/1306767/0/en/Aeolus-Announces-6-75-Million-Private-Placement-Financing.html</guid> <link>https://www.globenewswire.com/news-release/2015/12/14/1306767/0/en/Aeolus-Announces-6-75-Million-Private-Placement-Financing.html</link> <title>Aeolus Announces $6.75 Million Private Placement Financing</title> <description><![CDATA[<p> <span class="mw_region">MISSION VIEJO, CA</span><span>--(Marketwired - December 14, 2015) - </span> <a href="http://www.aeoluspharma.com/" rel="nofollow" title="Aeolus Pharmaceuticals, Inc.">Aeolus Pharmaceuticals, Inc.</a> (<exchange name="OTCQB">OTCQB</exchange>: <ticker name="AOLS">AOLS</ticker>), a biotechnology company developing compounds to protect against fibrosis, inflammation, nerve damage and infection announced today that it has entered into definitive agreements with certain institutional and other accredited investors to raise gross proceeds of $6.75 million in a private placement financing. The investors comprised both new and existing investors in the Company, including entities associated with BVF Partners L.P., a leading life sciences investment firm, which manages the Biotechnology Value Fund family of funds ("BVF"). </p>]]></description> <pubDate>Mon, 14 Dec 2015 12:00 GMT</pubDate> <dc:identifier>1306767</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Aeolus Pharmaceuticals</dc:contributor> <dc:modified>Wed, 14 Feb 2018 05:50 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2015/11/04/1306765/0/en/Aeolus-Announces-Formation-of-Pulmonary-Fibrosis-Clinical-Advisory-Board.html</guid> <link>https://www.globenewswire.com/news-release/2015/11/04/1306765/0/en/Aeolus-Announces-Formation-of-Pulmonary-Fibrosis-Clinical-Advisory-Board.html</link> <title>Aeolus Announces Formation of Pulmonary Fibrosis Clinical Advisory Board</title> <description><![CDATA[<p><span class="mw_region">MISSION VIEJO, CA</span><span>--(Marketwired - November 04, 2015) - </span><a href="http://www.aeoluspharma.com/" rel="nofollow" title="Aeolus Pharmaceuticals, Inc.">Aeolus Pharmaceuticals, Inc.</a> (<exchange name="OTCQB">OTCQB</exchange>: <ticker name="AOLS">AOLS</ticker>), a biotechnology company developing compounds to protect against fibrosis, inflammation, nerve damage and infection announced the formation of its Pulmonary Fibrosis Clinical Advisory Board ("PFCAB"). The PFCAB will be a critical strategic resource to the Company as it plans to file its Investigational New Drug Application with the FDA during the first quarter of 2016 and initiate clinical trials in pulmonary fibrosis shortly thereafter.</p>]]></description> <pubDate>Wed, 04 Nov 2015 13:30 GMT</pubDate> <dc:identifier>1306765</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Aeolus Pharmaceuticals</dc:contributor> <dc:modified>Wed, 14 Feb 2018 05:50 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2015/11/02/1306763/0/en/Aeolus-Receives-Notice-of-Patent-Allowance-for-New-Compound-That-Demonstrated-Efficacy-in-Michael-J-Fox-Foundation-Research-Grant-Program.html</guid> <link>https://www.globenewswire.com/news-release/2015/11/02/1306763/0/en/Aeolus-Receives-Notice-of-Patent-Allowance-for-New-Compound-That-Demonstrated-Efficacy-in-Michael-J-Fox-Foundation-Research-Grant-Program.html</link> <title>Aeolus Receives Notice of Patent Allowance for New Compound That Demonstrated Efficacy in Michael J. Fox Foundation Research Grant Program</title> <description><![CDATA[<p><span class="mw_region">MISSION VIEJO, CA</span><span>--(Marketwired - November 02, 2015) - </span></p>]]></description> <pubDate>Mon, 02 Nov 2015 13:30 GMT</pubDate> <dc:identifier>1306763</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Aeolus Pharmaceuticals</dc:contributor> <dc:modified>Wed, 14 Feb 2018 05:50 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2015/08/18/1306761/0/en/Aeolus-Announces-Publication-of-Study-Showing-AEOL-10150-Improves-Memory-and-Protects-Brain-Damage-in-an-Animal-Model-of-Epilepsy.html</guid> <link>https://www.globenewswire.com/news-release/2015/08/18/1306761/0/en/Aeolus-Announces-Publication-of-Study-Showing-AEOL-10150-Improves-Memory-and-Protects-Brain-Damage-in-an-Animal-Model-of-Epilepsy.html</link> <title>Aeolus Announces Publication of Study Showing AEOL 10150 Improves Memory and Protects Brain Damage in an Animal Model of Epilepsy</title> <description><![CDATA[<p><span class="mw_region">MISSION VIEJO, CA</span><span>--(Marketwired - August 18, 2015) - </span> </p>]]></description> <pubDate>Tue, 18 Aug 2015 12:00 GMT</pubDate> <dc:identifier>1306761</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Aeolus Pharmaceuticals</dc:contributor> <dc:modified>Wed, 14 Feb 2018 05:50 GMT</dc:modified> </item> </channel> </rss>